Skip to content

Clinical study to evaluate the Efficacy & Safety of DENTORA�® Gel in the management of Infectious-inflammatory diseases of the the oral cavity.

A prospective, Interventional, Randomized, parallel, active-controlled comparative clinical study to evaluate the Efficacy & Safety of DENTORA�® Gel in the management of Infectious-inflammatory diseases of the periodontium and mucosa of the oral cavity. - NA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031812
Enrollment
80
Registered
2021-03-08
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K055- Other periodontal diseases

Interventions

Intervention1: DENTORA�® GEL: GEL as a thin layer on the gums twice daily using a finger or swab.(As applicable) The treatment duration will be 7 days Control Intervention1: Metrogyl Denta: GEL as

Sponsors

AGIO PHARMACEUTICALS LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Both males and Females of Age � 6 years to 50, without any known allergy to commercial dental products or cosmetics. 2.Subject who meets with anyone of the following Infectious-inflammatory diseases of the parodontium and mucosa of the oral cavity

Exclusion criteria

Exclusion criteria: 1.Subjects who report history or presence of kidney disorders, kidney stones, have celiac disease, inflammatory bowel disease , chronic pancreatitis, have had intestinal or weight-loss surgery, or if have stomach or intestinal problems that keep them from absorbing certain foods or nutrients. 2.Subjects with eating disorders, uncontrolled Gastroesophageal reflux disease GERD or Acid Reflux, excessive dietary or environmental exposure to acids, or other systemic conditions that are predisposing to dentinal hypersensitivity. 3.Subjects with chronic medical debilitating disease associated with constant or intermittent episodes of daily pain. 4.Long-term daily use more than 7 consecutive days of analgesics and any other drugs that at the discretion of the Investigator would compromise the response of the hypersensitivity assessments.

Design outcomes

Primary

MeasureTime frame
1.Evaluation of Tooth sensitivity reduction in Mean Cold Air VAS Stimulus Score using Heft parker Visual Analog Scale 2. Evaluation of Reduction in gingivitis levels (bleeding on probing) assessed by the Gingival Bleeding Index (GBI)Timepoint: baseline day1 day 5, day 7 and day 10

Secondary

MeasureTime frame
1.Evaluation of the changes in deep tooth stains from screening to EOT by Lobene Stain index 2.Evaluation of the changes in tooth mobility for loose tooth roots from screening to EOT by mobility grading 3.Improvement in overall oral health performance is assessed by Oral Health Assessment Tool for Dental Screening and Oral care Assessment Guide 4.Incidence and Rate of adverse eventsTimepoint: baseline day1 day 5, day 7 and day 10

Countries

India

Contacts

Public ContactDr Harish S

ICBio Clinical Research Pvt. Ltd.

harish@icbiocro.com9900111997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026